Compare Stocks

→ Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars (From GoldenCrest Metals) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACST Acasti Pharma	$2.88 +1.1%	$3.32	$1.72 ▼ $3.84	$27.07M	1.49	26,505 shs	4,477 shs
MACK Merrimack Pharmaceuticals	$14.73	$14.71	$11.53 ▼ $15.89	$214.05M	1.43	114,262 shs	79,779 shs
NMUS Nemus Bioscience	$0.65 -9.5%	$10.59	$0.05 ▼ $0.74	$87.04M	-0.04	377,395 shs	1.00 million shs
SBPH Spring Bank Pharmaceuticals		$8.00	$0.80 ▼ $4.80	$122.94M	1.07	177,606 shs	N/A
UMRX Cogent Biosciences	$6.96 -2.2%	$10.50	$0.29 ▼ $3.72	$295.58M	3.93	1.22 million shs	1.21 million shs

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACST Acasti Pharma	+1.05%	-14.54%	-15.29%	+19.50%	+0.13%
MACK Merrimack Pharmaceuticals	0.00%	+0.34%	-0.41%	+11.09%	+21.04%
NMUS Nemus Bioscience	0.00%	-94.93%	-94.58%	-71.74%	+4,477.46%
SBPH Spring Bank Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
UMRX Cogent Biosciences	-2.25%	+7.74%	+8.92%	+50.32%	-38.08%

Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars (Ad)

Big Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.

Learn More Now

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACST Acasti Pharma	2.5252 of 5 stars	3.5	5.0	0.0	0.0	0.6	0.8	1.3
MACK Merrimack Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NMUS Nemus Bioscience	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SBPH Spring Bank Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
UMRX Cogent Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACST Acasti Pharma	3.00	Buy	$6.00	108.33% Upside
MACK Merrimack Pharmaceuticals	N/A	N/A	N/A	N/A
NMUS Nemus Bioscience	N/A	N/A	N/A	N/A
SBPH Spring Bank Pharmaceuticals	N/A	N/A	N/A	N/A
UMRX Cogent Biosciences	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest MACK, SBPH, UMRX, ACST, and NMUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
2/7/2024	ACST Acasti Pharma	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00

(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACST Acasti Pharma	N/A	N/A	N/A	N/A	$9.14 per share	N/A
MACK Merrimack Pharmaceuticals	N/A	N/A	N/A	N/A	$1.31 per share	N/A
NMUS Nemus Bioscience	N/A	N/A	N/A	N/A	($0.12) per share	N/A
SBPH Spring Bank Pharmaceuticals	N/A	N/A	N/A	N/A	$2.16 per share	N/A
UMRX Cogent Biosciences	$22.50M	13.14	N/A	N/A	$1.04 per share	6.69

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACST Acasti Pharma	-$42.43M	-$5.08	N/A	N/A	N/A	N/A	-13.18%	-11.32%	6/28/2024 (Estimated)
MACK Merrimack Pharmaceuticals	-$1.18M	-$0.08	N/A	∞	N/A	N/A	-6.24%	-6.09%	5/2/2024 (Estimated)
NMUS Nemus Bioscience	-$19.19M	N/A	0.00	∞	N/A	N/A	N/A	-924.42%	N/A
SBPH Spring Bank Pharmaceuticals	-$24.10M	-$1.47	N/A	N/A	N/A	N/A	-89.89%	-52.89%	N/A
UMRX Cogent Biosciences	-$31.83M	-$1.04	N/A	N/A	N/A	-96.84%	-87.78%	-52.14%	N/A

Latest MACK, SBPH, UMRX, ACST, and NMUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/7/2024	Q4 2023	MACK Merrimack Pharmaceuticals	N/A	-$0.01	-$0.01	-$0.01	N/A	N/A
2/12/2024	12/31/2023	ACST Acasti Pharma	-$0.23	-$0.21	+$0.02	-$0.21	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACST Acasti Pharma	N/A	N/A	N/A	N/A	N/A
MACK Merrimack Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NMUS Nemus Bioscience	N/A	N/A	N/A	N/A	N/A
SBPH Spring Bank Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UMRX Cogent Biosciences	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACST Acasti Pharma	N/A	15.19	15.19
MACK Merrimack Pharmaceuticals	N/A	43.50	43.50
NMUS Nemus Bioscience	N/A	0.12	0.12
SBPH Spring Bank Pharmaceuticals	N/A	5.11	5.11
UMRX Cogent Biosciences	0.18	2.90	2.90

Ownership

Institutional Ownership

Company	Institutional Ownership
ACST Acasti Pharma	6.08%
MACK Merrimack Pharmaceuticals	63.97%
NMUS Nemus Bioscience	N/A
SBPH Spring Bank Pharmaceuticals	17.17%
UMRX Cogent Biosciences	26.39%

Insider Ownership

Company	Insider Ownership
ACST Acasti Pharma	13.51%
MACK Merrimack Pharmaceuticals	30.57%
NMUS Nemus Bioscience	2.70%
SBPH Spring Bank Pharmaceuticals	12.70%
UMRX Cogent Biosciences	31.50%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ACST Acasti Pharma	32	9.40 million	8.13 million	Not Optionable
MACK Merrimack Pharmaceuticals	426	14.53 million	10.09 million	Optionable
NMUS Nemus Bioscience	N/A	133.91 million	N/A	Not Optionable
SBPH Spring Bank Pharmaceuticals	30	17.27 million	N/A	Not Optionable
UMRX Cogent Biosciences	72	42.47 million	N/A	Not Optionable

MACK, SBPH, UMRX, ACST, and NMUS Headlines

Source	Headline
	Cogent Biosciences Inc money.usnews.com - April 24 at 4:34 AM
	Analysts Conflicted on These Healthcare Names: Cogent Biosciences (COGT) and Altimmune (ALT) markets.businessinsider.com - February 26 at 5:33 PM
	Analysts Have Conflicting Sentiments on These Healthcare Companies: Cogent Biosciences (COGT) and Moderna (MRNA) markets.businessinsider.com - February 26 at 8:53 AM
	Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results markets.businessinsider.com - February 26 at 8:53 AM
	Buy Rating Affirmed for Cogent Biosciences Ahead of Key Data Presentation on Bezuclastinib with Strong Upside Potential markets.businessinsider.com - February 15 at 8:43 AM
	Cogent Biosciences Stock Soars After $225M Private Placement marketwatch.com - February 14 at 10:02 AM
	Cogent Biosciences announces oversubscribed $225M private placement msn.com - February 14 at 10:02 AM
	Buy Rating on Cogent Biosciences Amid Market Overreaction and Promising Drug Prospects markets.businessinsider.com - February 9 at 2:23 AM
	Citi starts Cogent Biosciences at buy, cites GI tumor drug potential msn.com - February 8 at 4:22 PM
	Buy Rating Reiterated for Cogent Biosciences as Bezuclastinib Shows Promise in SUMMIT Trial markets.businessinsider.com - December 15 at 7:55 PM
	Maintaining Buy on Cogent Biosciences Amid Anticipation of Differentiating Data for Bezuclastinib markets.businessinsider.com - December 13 at 5:33 PM
	Dow Surges 100 Points; Cogent Biosciences Shares Plunge markets.businessinsider.com - December 11 at 12:21 PM
	Cogent Biosciences Shares Fall Despite Positive Clinical Trial Updates For Systemic Mastocytosis Treatment markets.businessinsider.com - December 11 at 12:21 PM
	Cogent Reports Positive Data From Phase 2 APEX Trial Of Bezuclastinib In Systemic Mastocytosis markets.businessinsider.com - December 11 at 10:08 AM
	Cogent slumps after mid-stage data for rare disorder therapy msn.com - December 11 at 10:08 AM
	Potential Upside for Cogent Biosciences Due to Imminent Data Readout for Bezuclastinib and Underpriced Shares markets.businessinsider.com - November 21 at 9:11 AM
	Promising Clinical Trials and Strong Financial Position Justify Buy Rating for Cogent Biosciences markets.businessinsider.com - November 14 at 8:40 AM
	Promising Clinical Trials and Strong Financial Position Support Buy Rating for Cogent Biosciences markets.businessinsider.com - November 4 at 5:21 PM
	Promising Market Potential for Cogent Biosciences’ Bezuclastinib Spurs Buy Rating markets.businessinsider.com - October 28 at 7:55 AM
	Analyst Expectations for Cogent Biosciences's Future benzinga.com - August 30 at 8:53 AM
	Cogent Biosciences Is Beginning To Differentiate Its KIT Inhibitor msn.com - August 15 at 5:40 PM
	LifeSci Capital Remains a Buy on Cogent Biosciences (COGT) markets.businessinsider.com - August 8 at 3:59 PM
	Does Cogent Biosciences, Inc. (COGT) Have the Potential to Rally 78.9% as Wall Street Analysts Expect? msn.com - July 11 at 1:47 PM
	Cogent Biosciences Shares Rise on Fairmount Funds Management's Stake Acquisition marketwatch.com - June 13 at 11:04 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Acasti Pharma

NASDAQ:ACST

Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Merrimack Pharmaceuticals

NASDAQ:MACK

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Nemus Bioscience

OTCMKTS:NMUS

Nemus Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics. The company's product candidates in preclinical stage include NB1111 for the treatment of glaucoma; NB1222 used for treating chemotherapy induced nausea and vomiting; and NB3111 for the treatment of methicillin-resistant staphylococcus aureus. Its products under research comprise NB2111 for use in treating chemotherapy induced peripheral neuropathy; and NB2222 for the treatment of uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy. Nemus Bioscience, Inc. has a license agreement with the University of Mississippi to research, develop, and commercialize products for the treatment of infectious diseases. The company was founded in 2012 and is headquartered in Costa Mesa, California.

Spring Bank Pharmaceuticals

NASDAQ:SBPH

Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of a range of cancers and inflammatory diseases using its proprietary small molecule nucleotide platform. The company is developing SB 11285, a next-generation immunotherapeutic cyclic dinucleotide for the treatment of selected cancers; novel STING antagonist compounds for the treatment of autoimmune and inflammatory diseases; and novel platform to enable the targeted delivery of payload molecules. It has a collaboration agreement with with Roche to explore the co-administration of SB 11285. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.

Cogent Biosciences

NASDAQ:UMRX

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial